DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact CDER Office of Compliance at 301-796-3130 or wdd3plrequirements@fda.hhs.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2014 Procedural

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

Guidance for Industry

Additional copies are available from:
Office of Communications
Division of Drug Information,
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Avenue
Hillandale Building, 4th Floor, 4147
Silver Spring, MD 20993

Phone: 301-796-3400 or 855-543-3784; Fax: 301-431-6353

druginfo@fda.hhs.gov

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or

> Office of Communication, Outreach and Development, WO71, Room 3128 Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, MD 20993 Phone: 800-835-4709 or 240-402-7800

ocod@fda.hhs.gov

http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2014 Procedural

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION	. 1
II.	BACKGROUND	. 2
III.	WHO MUST REPORT	. 2
A.	Prescription Drug Wholesale Distributors	2
В.	Third-Party Logistics Providers	2
C.	Dual Roles	3
IV.	WHAT SHOULD BE REPORTED	. 3
A.	Discussion	3
В.	Initial Report	3
C.	Subsequent Reports	6
V.	WHEN TO REPORT	. 6
A.	Initial Report	6
В.	Subsequent Annual Reports	6
C.	Significant Disciplinary Action Reports	6
D.	Other Voluntary Reports	6
VI.	HOW TO REPORT	. 7
A.	Format	7
В.	Submission	7
VII.	PUBLIC AVAILABILITY OF INFORMATION	. 7

Draft — Not for Implementation

Guidance for Industry¹

Drug Supply Chain Security Act Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance describes FDA's expectations for prescription drug wholesale distributors (wholesale distributors) and third-party logistics providers (3PLs) for the annual reporting to FDA as required under the Drug Supply Chain Security Act of 2013 (DSCSA). Under section 584(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee-3(b)), beginning November 27, 2014, 3PLs must report certain information to FDA, including State licensure information for each facility and the name and address for each facility. Under section 503(e)(2)(A) (21 U.S.C. 353(e)(2)(A) (as amended by the DSCSA), beginning January 1, 2015, wholesale distributors also must report certain information to FDA, including State licensure information for each facility, contact information for each facility, and any significant disciplinary actions taken by a State or the Federal Government. This guidance outlines the information that should be submitted to FDA, the timing of the submissions, a preferred format for the submissions, and a preferred method for reporting to FDA.

This guidance does not address all requirements described in the DSCSA for wholesale distributors and 3PLs pursuant to sections 503(e)(2) and 584. The information provided in this guidance is limited to reporting of information by wholesale distributors and 3PLs. Some information outlined in the guidance is required to be reported under section 503(e)(2)(A) and section 584(b) of the FD&C Act, as amended by the DSCSA.

 FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word "should" in Agency guidances means that something is suggested or recommended, but not required.

¹ This guidance has been prepared by the Office of Compliance in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER).

Draft — Not for Implementation

II. BACKGROUND

On November 27, 2013, the DSCSA (Title II of Public Law 113-54) was signed into law. The DSCSA outlines new requirements to develop and enhance drug distribution security over the next 10 years, including establishing national standards for the licensing of prescription drug wholesale distributors and 3PLs.

Section 204 of the DSCSA amends section 503(e) of the FD&C Act and outlines requirements for reporting by wholesale distributors. Section 503(e)(2)(A) of the FD&C Act (as amended) requires wholesale distributors to report certain information annually, beginning on January 1, 2015. Information to be reported includes State licensure information and contact information for each facility. Wholesale distributors must also report to FDA any significant disciplinary actions taken by the State or Federal Government, such as revocation or suspension of a license. Section 204 of the DSCSA also amends section 503(e)(2)(B) of the FD&C Act and requires FDA to make certain information about wholesale distributors' licensure available to the public on FDA's Web site. Updates to the public information are to be made on a schedule to be determined by FDA.

Section 205 of the DSCSA adds section 584 to the FD&C Act. Section 584 sets forth requirements for licensure and reporting by 3PLs. Under section 584(b) of the FD&C Act (as amended), 3PLs must report annually to FDA, beginning on November 27, 2014 (1 year after the date of enactment of the DSCSA). Third-party logistic providers must report State licensure information, the name and address for each facility, and all trade names under which each facility conducts business.

III. WHO MUST REPORT

A. Prescription Drug Wholesale Distributors

Section 503(e)(2)(A) requires that any person who owns or operates an establishment that engages in wholesale distribution, as defined in section 503(e)(4) of the FD&C Act, as amended by the DSCSA, must report. Companies should refer to the applicable definitions in section 503(e)(4) of the FD&C Act to determine if they conduct wholesale distribution and would be required to report annually to FDA.

B. Third-Party Logistics Providers

 Section 584 requires that any facility of a 3PL, as defined in section 581(22) of the FD&C Act, as amended by DSCSA, must report. A 3PL is an entity that provides or coordinates warehousing, or other logistics services of a product² in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser of a product, but does not take ownership of the product, nor have responsibility to direct the sale or disposition of the product.

² Product as defined under section 581(13) of the FD&C Act (21 U.S.C. 360eee), as amended by the DSCSA.

Draft — Not for Implementation

85	
86	

C. Dual Roles

Any person or entity that acts as both a wholesale distributor and a 3PL is subject to the reporting requirements of both section 503(e)(2) and section 584. The person or entity should report according to the relevant requirement for each respective facility. If a company conducts both prescription drug wholesale distribution and 3PL services from the same facility, that facility should be reported separately under each category as a wholesale distributor and a 3PL.

IV. WHAT SHOULD BE REPORTED

A. Discussion

The DSCSA requires FDA to make a database of authorized wholesale distributors available to the public on FDA's Web site. In addition, FDA believes it would be helpful for enforcement of the DSCSA to make information about 3PLs available on FDA's Web site, because having the license status of 3PLs in one publicly available database would be helpful for FDA, trading partners, and other stakeholders, in determining whether 3PLs are authorized or not. Therefore, all of the information reported to the FDA may be made available to the public on the FDA Web site, to the extent allowable by law.

The DSCSA requires contact information to be submitted by wholesale distributors. FDA considers contact information to include the email address and telephone number of the person who will interact with the FDA. In addition to the specific information required by DSCSA to be submitted to the Agency, FDA has identified additional information that will enhance efficiencies and improve accuracy in the management of the licensing and facility information submitted to the Agency. Therefore, FDA is requesting that certain additional information be submitted to FDA on a voluntary basis. This additional information will be useful to FDA in its enforcement of the Act and to stakeholders as they make decisions about their drug product distribution. Furthermore, FDA is requesting the same information from wholesale distributors and 3PLs. The ultimate goal is for the public database to serve as a single repository of licensing and facility information for wholesale drug distributors and 3PLs conducting business in the

United States.

B. Initial Report

The initial report from a wholesale distributor is the first report submitted to FDA to meet the reporting requirements under section 503(e)(2)(A) of the FD&C Act, as amended by the DSCSA.

1. For each facility, a wholesale distributor must provide:

a) Identifying information for the facility

 Name of company (FDA recommends providing the company name in the same form as it appears on the license)

• Address of the facility

Draft — Not for Implementation

128 129		•	Contact information (FDA recommends providing the name of a contact person to interact with FDA, an email address and a
130			telephone number)
131		•	All trade names that the company does business as (i.e., any other
132			names listed as "dba")
133			
134		b)	Licensure information for each State
135		•	State
136		•	State license number (identification number)
137		•	Significant disciplinary actions by any State or Federal agency
138			(FDA recommends describing any significant disciplinary action
139			that occurred in the 12 months preceding the initial report by
140			identifying the type of disciplinary action, the date of final
141			disciplinary action, and the state where the disciplinary action
142			occurred)
143			,
144			
145	2.	For e	ach facility, a wholesale distributor should provide:
146		a)	Unique facility identifier
147		b)	Expiration date for the license
148		c)	Documents associated with the disciplinary action, such as a
149			consent decree, final State Board ruling, etc.
150			
151	The initial report fro	m a 3PI	L is the first report submitted to FDA to meet the reporting
152	requirements under s	section 5	584(b) of the FD&C Act, as amended by the DSCSA.
153			
154	1.	For e	ach facility, a 3PL must provide:
155		a)	Name of company (FDA recommends providing the company
156			name in the same form as it appears on the license)
157		b)	Address of the facility
158		c)	All trade names that the company does business as (i.e., any other
159			names listed as "dba")
160		d)	Licensure information for each State
161		•	State
162		•	State license number (identification number)
163			
164	2.	For e	ach facility, a 3PL should provide:
165		a)	Name of contact person to interact with FDA
166		b)	Email address
167		c)	Telephone number
168		d)	Unique facility identifier
169		e)	Expiration date for the license
170		f)	Significant disciplinary actions by any State or Federal agency that
171			occurred in the 12 months preceding the initial report the past 1
172			year
173		•	State where disciplinary action occurred

Draft — Not for Implementation

- Date of final action
 Type of disciplinary action
 Description of violation
 - Documents associated with the disciplinary action, such as a consent decree, final State Board ruling, etc.

In addition to the name and address of the facility, FDA is requesting that wholesale distributors and 3PLs submit a unique facility identifier for each facility. The site-specific unique facility identifier for a facility is a useful resource for FDA in identifying and confirming certain business information for that entity. The current unique facility identifier preferred by FDA is the D-U-N-S® number. Businesses may obtain D-U-N-S® numbers for no cost directly from Dun & Bradstreet (D&B) (http://www.dnb.com).

State license information must be provided for each State from which the drug products are distributed with State licensure programs and for each State that requires a license to ship product into that State. Third-party logistics providers are considered to be licensed under section 582(a)(7) of the FD&C Act (as amended) (21 U.S.C. 360eee-1) until the effective date of the 3PL licensing regulations and may not have information to report to FDA about specific State licensure unless a State has a 3PL licensing program. However, 3PLs are still required to report to the FDA under the DSCSA.

FDA is also requesting submission of the date(s) that State license(s) expires. This information is essential for determining the licensure status for each wholesale distributor and 3PL facility during the reporting period. Pursuant to section 503(e)(1) of the FD&C Act, as amended by the DSCSA, wholesale distributors will be licensed by the State from which the drug is distributed or by FDA if the State from which the drug is distributed has not established a licensure program. Wholesale distributors will also be licensed by the State into which the drug is distributed if required by that State. Similarly, pursuant to 584(a) of the FD&C Act, as amended by the DSCSA, 3PLs will be licensed by the State from which the drug is distributed or by FDA if the State has not established a licensure program. And 3PLs will be licensed by the State into which the drug is distributed if that State requires the licensure of a person that distributes drugs into the State and the 3PL is not licensed by FDA.

Significant disciplinary actions taken against wholesale distributors must be reported to FDA, as required under section 503(e)(2)(ii) of the FD&C Act, as amended by the DSCSA. In addition, FDA is requesting that 3PLs report significant disciplinary actions to FDA. It is important for FDA and others to know whether a wholesale distributor or 3PL has had a license revoked or suspended or whether a wholesale distributor or 3PL has had any other significant disciplinary actions taken against them that limits the ability of a facility to conduct drug-related business. Reports of significant disciplinary actions should include any action by State or Federal government that limits or prevents a wholesale distributor or 3PL from distributing or facilitating

³ As explained in FDA's *Guidance for Industry: Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration* (available at http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugsgen/documents/document/ucm367199.pdf), alternative identifiers can also be used by contacting FDA.

Draft — Not for Implementation

				· · · · · · · · · · · · · · · · · · ·				
215 216	the dis		on of pro	escription drugs, including for-cause revocation, termination, or suspension				
217	or a nc	tense.						
218		C.	Subse	equent Reports				
219		C.	Subsc	quent Reports				
220	To me	et the (continui	ng reporting requirements under sections 503(e)(2)(A) and 584(b) of the				
221			as amended by DSCSA, any reports from a wholesale distributor or 3PL submitted					
222			the "Initial Report" for a particular facility is considered a subsequent report for					
223	that facility. The required and voluntary components of subsequent reports are the same as those							
224	for init	tial rep	orts.					
225								
226227	V.			REPORT				
228			-	n describes the time frames for reporting for wholesale distributors and				
229				the reporting requirements under DSCSA and provide additional				
230				voluntarily. If a company chooses to update expired licenses during a time				
231				annual reporting time period as defined below, the company should still				
232	report	during	the defi	ned annual reporting period.				
233								
234		A.	Initia	l Report				
235								
236			1.	Wholesale distributors: January 1, 2015–March 31, 2015				
237			2.	3PLs: November 27, 2014–March 31, 2015				
238			3.	Wholesale distributor and 3PL facilities that are newly licensed after the				
239				dates noted above should initially report within 30 days of obtaining a				
240				State or Federal license.				
241		_	~ •					
242		В.	Subse	equent Annual Reports				
243			,					
244			1.	Wholesale distributors: January 1–March 31 annually				
245			2.	3PLs: January 1–March 31 annually				
246		~	g	" (T) ' II				
247		C.	Signii	icant Disciplinary Action Reports				
248	Damant	c .:	: £:	t disciplinary actions should be submitted to EDA when a final action on				
249		Reports of significant disciplinary actions should be submitted to FDA when a final action or						
250	runng	nas be	en made	by a State or Federal licensing authority.				
251			1	Wholesale distributors, within 20 days of final action				
252			1. 2.	Wholesale distributors: within 30 days of final action				
253254			۷.	3PLs: within 30 days of final action				
254 255		D	Other	Voluntory Donorts				
255 256		D.	Omer	· Voluntary Reports				
250 257	A com	nanva	hould n	otify FDA if a facility goes out of business or decides to voluntarily				
258				Federal license.				
	williui	uvv a D	rate of I	cuciui iiceiige.				

259

Draft — Not for Implementation

Out of business: within 30 days of business closing
 Voluntary withdrawal of a State license: within 30 days

VI. HOW TO REPORT

A. Format

FDA prefers the use of extensible markup language (XML) files in a standard Structured Product Labeling $(SPL)^4$ format.

B. Submission

FDA is providing a method to enter and submit the required and voluntary reporting and significant disciplinary actions for wholesale distributors and 3PLs. A link to the Web portal can be accessed from FDA's Web site. Wholesale distributors and 3PLs should access FDA's Web page at http://www.fda.gov/wdd3plreporting and follow the instructions to complete the required and voluntary reporting. Companies using the FDA Web portal for entry and submission will not have to convert the information to XML in the SPL format; appropriate formatting will happen automatically via the web portal. This portal will allow a company to act as a reporter for all of the facilities that they own without having to create a separate account for each facility. If the reporter wants to enter information for multiple facilities, contact information about the reporter, including the reporter's UFI, will be needed. An alternative method for reporting is to submit an XML file in the SPL format via an account through the FDA Electronic Submissions Gateway (ESG). If you want to use an alternative method for your submissions, contact FDA via email at wDD3PLRequirements@fda.hhs.gov for more information.

VII. PUBLIC AVAILABILITY OF INFORMATION

FDA will make the information collected publically available on its Web site. FDA plans to make the wholesale distributor and 3PL significant disciplinary action information publicly available to the extent allowable by law. This information will be updated on a regular basis. The public information will be available for download from FDA's Web site at http://www.fda.gov/wdd3plreporting.

⁴ SPL is a Health Level Seven, Inc., standard for the exchange of product information using XML.